Form 4: Clorox Executive Defers Stock Grant, Reports Tax Withholding

Clorox EVP Stacey Grier reported the future settlement of a performance unit grant and subsequent tax-related share dispositions, deferring a significant portion.

Summary

• Stacey Grier, EVP Executive Chief of Staff at Clorox Co. (CLX), reported transactions occurring on October 3, 2025.
• Acquired 9,913 shares of Common Stock at $122.25 per share, stemming from the settlement of a 2022 Performance Unit Grant that vested on 10/03/2025.
• Elected to defer the settlement of these shares pursuant to the 2005 Stock Incentive Plan.
• Disposed of 233 shares at $122.25 to satisfy tax obligations related to the vesting of performance stock units.
• Disposed of an additional 799 shares at $122.25 to satisfy tax obligations related to the vesting of restricted stock.
• Beneficial ownership after these transactions is 32,203 shares.
• The reported beneficial ownership includes 1,004 shares acquired through a dividend reinvestment feature of the Company's Stock Incentive Plan.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation event, including the vesting of performance units and tax-related share dispositions. The deferral of the grant and dividend reinvestment are mildly positive signals of executive confidence and long-term alignment, but the overall impact is neutral as it's a pre-planned, non-discretionary transaction.

Positives

• Executive Stacey Grier acquired 9,913 shares through a performance unit grant, indicating successful achievement of performance targets.
• The election to defer the settlement of shares suggests a long-term commitment to the company and potential confidence in future stock performance.
• The inclusion of 1,004 shares from dividend reinvestment indicates participation in a plan that grows ownership over time.

Negatives

• Dispositions of 233 shares and 799 shares were made to cover tax obligations, which is a common practice but reduces direct share ownership.

Future Outlook

The filing indicates a future transaction date of October 3, 2025, for the vesting and settlement of a 2022 Performance Unit Grant, with the reporting person electing to defer the settlement. This suggests a pre-planned event, likely under a Rule 10b5-1 plan, and reflects future compensation realization.

Management Comments

• The reporting person has elected to defer the settlement of the 2022 Performance Unit Grant pursuant to the 2005 Stock Incentive Plan.

Industry Context

This is a routine insider transaction filing (Form 4) for executive compensation. It doesn't provide broader industry trends but reflects standard practices for executive stock grants and tax management in publicly traded companies.

Comparison to Industry Standards

• The vesting of performance units and subsequent tax withholding are standard practices for executive compensation in publicly traded companies across various industries, including consumer staples like Clorox.
• Deferring stock settlement is a common strategy for executives to manage tax liabilities and demonstrate long-term commitment, similar to practices at peers like Procter & Gamble (PG) or Kimberly-Clark (KMB).
• The use of a Rule 10b5-1 plan for these transactions is a standard corporate governance practice to avoid accusations of insider trading.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor positive impact from executive deferring shares, indicating long-term commitment. Tax-related sales are routine.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, specifically the vesting of performance units and subsequent tax-related share dispositions, along with a deferral election. While the deferral and dividend reinvestment are mildly positive signals of executive alignment, these are pre-planned, non-discretionary transactions that do not reflect new strategic developments or significant changes in the company's fundamental outlook. Therefore, it provides no new information to warrant a change in investment recommendation; a 'hold' stance remains appropriate based solely on this filing.

Keywords

Clorox, CLX, Stacey Grier, Insider Transaction, Form 4, Stock Grant, Performance Units, Tax Withholding, Executive Compensation, Share Ownership, 10b5-1 Plan